Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-18 23:05 | 2024-10-16 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $41.36 | 5,833 | $241,253 | 11,000 | -34.7% |
| 2024-10-04 23:06 | 2024-10-02 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $40.35 | 5,833 | $235,362 | 11,000 | -34.7% |
| 2024-09-20 23:05 | 2024-09-18 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $45.54 | 5,834 | $265,680 | 11,000 | -34.7% |
| 2024-09-05 23:06 | 2024-09-04 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $48.58 | 5,000 | $242,900 | 11,000 | -31.3% |
| 2022-06-07 23:03 | 2022-06-03 | AKBA | Akebia Therapeutics Inc. | GILMAN STEVEN C | Director | Pharmaceutical Preparations | SALE | $0.36 | 4,567 | $1,653 | 43,430 | -9.5% |
| 2022-05-02 23:07 | 2022-04-29 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | SALE | $30.94 | 900 | $27,846 | 5,200 | -14.8% |
| 2021-12-02 00:07 | 2021-11-29 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $39.17 | 5,000 | $195,855 | 3,500 | -58.8% |
| 2021-10-28 23:12 | 2021-10-27 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $50.57 | 5,000 | $252,870 | 3,500 | -58.8% |
| 2021-10-01 23:12 | 2021-09-30 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $48.85 | 5,000 | $244,255 | 3,500 | -58.8% |
| 2021-06-09 23:26 | 2021-06-07 | AKBA | Akebia Therapeutics Inc. | GILMAN STEVEN C | Director | Pharmaceutical Preparations | SALE | $3.32 | 4,567 | $15,163 | 47,997 | -8.7% |
| 2020-12-23 17:06 | 2020-12-21 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Pharmaceutical Preparations | BUY | $6.25 | 4,000 | $25,000 | 4,000 | +100.0% |
| 2020-08-08 00:04 | 2020-08-05 | MNTA | N/A | GILMAN STEVEN C | Director | Other | OPT+S | $32.75 | 13,000 | $425,750 | 7,796 | -62.5% |
| 2020-07-31 02:03 | 2020-07-29 | MNTA | N/A | GILMAN STEVEN C | Director | Other | OPT+S | $29.70 | 10,000 | $297,000 | 7,796 | -56.2% |
| 2020-07-24 00:55 | 2020-07-22 | MNTA | N/A | GILMAN STEVEN C | Director | Other | OPT+S | $33.23 | 10,000 | $332,300 | 7,796 | -56.2% |
| 2020-06-09 23:17 | 2020-06-08 | AKBA | Akebia Therapeutics Inc. | GILMAN STEVEN C | Director | Pharmaceutical Preparations | SALE | $12.08 | 4,567 | $55,169 | 38,864 | -10.5% |
| 2019-11-22 14:20 | 2019-11-20 | AKBA | Akebia Therapeutics Inc. | GILMAN STEVEN C | Director | Pharmaceutical Preparations | BUY | $3.43 | 5,800 | $19,894 | 29,731 | +24.2% |
| 2019-05-03 23:07 | 2019-05-01 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $16.81 | 7,500 | $126,095 | 0 | -100.0% |
| 2019-03-05 00:01 | 2019-02-28 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $18.02 | 7,500 | $135,129 | 0 | -100.0% |
| 2018-12-05 00:05 | 2018-12-03 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $17.75 | 8,500 | $150,908 | 0 | -100.0% |
| 2018-09-06 23:05 | 2018-09-04 | VCEL | Vericel Corp | GILMAN STEVEN C | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $12.03 | 9,000 | $108,270 | 0 | -100.0% |
| 2018-06-26 23:29 | 2018-06-22 | MNTA | N/A | GILMAN STEVEN C | Director | Other | SALE | $21.50 | 2,294 | $49,321 | 3,440 | -40.0% |
| 2018-06-12 23:01 | 2018-06-11 | KERX | N/A | GILMAN STEVEN C | Director | Other | SALE | $5.12 | 1,334 | $6,830 | 17,333 | -7.1% |
| 2018-05-31 23:19 | 2018-05-29 | KERX | N/A | GILMAN STEVEN C | Director | Other | SALE | $5.22 | 1,333 | $6,958 | 18,667 | -6.7% |
| 2017-07-26 23:42 | 2017-07-25 | CFRX | N/A | GILMAN STEVEN C | Director, Officer; CEO | Other | BUY | $1.24 | 800 | $992 | 20,800 | +4.0% |
| 2016-07-28 00:18 | 2016-07-27 | CFRX | N/A | GILMAN STEVEN C | Director, Officer; CEO | Other | BUY | $2.48 | 20,000 | $49,600 | 20,000 | +100.0% |
| 2014-10-02 23:07 | 2014-10-01 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $65.39 | 48,125 | $3,146,711 | 27,598 | -63.6% |
| 2014-07-29 23:01 | 2014-07-28 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $61.57 | 40,625 | $2,501,103 | 27,598 | -59.5% |
| 2014-02-19 23:37 | 2014-02-18 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $75.00 | 2,645 | $198,375 | 24,493 | -9.7% |
| 2014-01-02 23:15 | 2014-01-02 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $67.82 | 25,000 | $1,695,443 | 23,540 | -51.5% |
| 2014-01-02 23:34 | 2014-01-02 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $67.82 | 25,000 | $1,695,443 | 22,778 | -52.3% |
| 2013-06-04 01:00 | 2013-06-03 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $54.49 | 15,125 | $824,204 | 23,507 | -39.2% |
| 2013-05-17 19:33 | 2013-05-16 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $48.88 | 1,201 | $58,700 | 23,507 | -4.9% |
| 2013-05-16 22:45 | 2013-05-15 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $48.41 | 1,017 | $49,238 | 22,208 | -4.4% |
| 2013-05-16 00:16 | 2013-05-14 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $49.18 | 1,135 | $55,818 | 20,725 | -5.2% |
| 2013-02-20 19:43 | 2013-02-19 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $41.40 | 1,233 | $51,047 | 18,360 | -6.3% |
| 2013-01-03 21:21 | 2013-01-02 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $42.98 | 15,000 | $644,745 | 15,843 | -48.6% |
| 2012-05-17 23:09 | 2012-05-17 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $41.57 | 20,000 | $831,466 | 18,379 | -52.1% |
| 2012-05-16 22:07 | 2012-05-15 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $41.88 | 1,597 | $66,875 | 18,379 | -8.0% |
| 2012-05-15 23:11 | 2012-05-14 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $41.55 | 1,135 | $47,162 | 14,976 | -7.0% |
| 2011-10-28 19:00 | 2011-10-26 | CBST | N/A | GILMAN STEVEN C | Officer; EVP & Chief Scientific Officer | Other | OPT+S | $38.70 | 71,250 | $2,757,596 | 12,480 | -85.1% |
| 2010-05-18 20:26 | 2010-05-17 | CBST | N/A | GILMAN STEVEN C | Officer; SVP, Chief Scientific Officer | Other | OPT+S | $21.81 | 1,035 | $22,577 | 5,599 | -15.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.